ERBB2 and breast carcinoma: The Phase III NATALEE study enrolled 5101 patients at any menopausal stage with stage > IIA HR+/HER2+ early breast cancer to evaluate the efficacy of ribociclib in combination with endocrine therapy over a 3-year treatment period.